5

Are FDA Delays Good or Bad for Investors?

Delays in particular can be difficult to decipher. They can sometimes signal serious problems that investors need to be wary of, and other times they just mean that the agency needs more time to analyze data. In the following video, our health care analyst Max Macaluso looks at how FDA delays can affect investors, and he draws from recent examples at fledgling orphan drugmaker Raptor Pharmaceutical (NASDAQ: RPTP) , Eliquis developers Pfizer (NYSE: PFE) and Bristol-Myers Squibb (NYSE: BMY) , obesity drugmaker VIVUS (NASDAQ: VVUS) , and inhalable insulin developer MannKind (NASDAQ: MNKD) .

The health care space may offer investors many opportunities, but this is also one of the market's riskiest sectors. Motley Fool co-founder David Gardner's picks, which range across many sectors, have frequently trounced the market.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.

Sending report...

Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo